Agonists of the glucagon-like peptide-1 receptor (GLP-1RAs) have emerged as effective treatments for obesity, but have a negative impact on lean mass during weight loss.
More than 30 years after entering the scene as a first-generation monoclonal antibody pioneer, Morphosys AG is to be acquired by Novartis AG for €2.7 billion (US$2.9 billion). The all-cash deal, announced after Nasdaq closed on Feb. 5, will see Novartis paying €68 per share, a premium of 94% to the average daily price in the month leading up to Jan. 25, when rumors of a takeover started swirling.
Previous research has shown that the three isoforms of transforming growth factor β (TGF-β) have distinct cellular expression patterns, with TGF-β2 and TGF-β3 expression being specifically elevated in human fibrotic lung and liver tissue. Since pan-TGF-β inhibition had proven to be toxic for chronic use, in recent work, researchers from Genentech Inc. aimed to assess whether specifically targeting one of the TGF-β isoforms could represent a novel therapeutic option for patients with chronic fibrotic disorders.
23andme Holding Co. has received FDA clearance of its IND application for 23ME-01473 (‘1473), a dual mechanism antibody and natural killer (NK) cell activator intended to treat cancer.
Domain Therapeutics SA has been awarded a grant as part of the Hospital-University Research in Health (RHU) SPRINT consortium, which seeks to progress a precision medicine for cutaneous T-cell lymphoma (CTCL).
Calluna Pharma Inc., formed last year following the merger of Oxitope Pharma BV and Arxx Therapeutics AS, has raised €75 million (US$81.4 million) in a series A financing.
Patients with celiac disease have gluten-specific CD4+ T cells that recognize gluten via disease-associated human leukocyte antigen (HLA) molecules, specifically HLA-DQ2.5, leading to immune activation and enteropathy.
Elpiscience Biopharma Ltd. and Astellas Pharma Inc. have announced a research collaboration and license agreement for two novel bispecific macrophage engagers – ES-019 and another program.
Biocytogen Pharmaceuticals Co. Ltd. and Ctm Biotech Co. Ltd. have reported progress in the development of a trispecific T-cell engager for an intracellular target.
RSS
